dimethyl 2,2-bis((1,3-dioxolan-2-yl)methyl)malonate | 819871-92-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: dimethyl 2,2-bis((1,3-dioxolan-2-yl)methyl)malonate
• 英文别名: Dimethyl 2,2-bis(1,3-dioxolan-2-ylmethyl)propanedioate
• CAS: 819871-92-6
• 化学式: C₁₃H₂₀O₈
• 分子量: 304.297
• InChiKey: VEIUXWRSJLPYHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  89.5
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  dimethyl 2,2-bis((1,3-dioxolan-2-yl)methyl)malonate 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 1-[(1S)-1-methylpropyl]-bis(methoxycarbonyl)-1,4-dihydropyridine
  参考文献：
  名称：

  Concise synthetic strategy toward cyclic α,α-disubstituted α-amino acids bearing a δ-nitrogen atom: chiral 1-substituted 4-aminopiperidine-4-carboxylic acids

  摘要：

  A concise synthetic strategy toward cyclic alpha,alpha-disubstituted alpha-amino acids, 1-substituted 4-aminopiperidine-4-carboxylic acids have been developed. The synthetic route is a reductive amination of dimethyl bis(dioxoianemethyl)malonate with various amines, followed by Curtius rearrangement. This synthetic route is capable of synthesizing 4-aminopiperidine-4-carboxylic acids bearing a bulky substituent and optically active ones bearing a pendent chiral substituent, by the change of condensed amines. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.11.004
• 作为产物：
  描述：

  2-溴甲基-1,3-二氧戊烷 、 丙二酸二甲酯 在 potassium tert-butylate 作用下， 以 二甲基亚砜 为溶剂， 反应 48.0h， 生成 dimethyl 2,2-bis((1,3-dioxolan-2-yl)methyl)malonate
  参考文献：
  名称：

  严重急性呼吸系统综合症冠状病毒木瓜蛋白酶样新型蛋白酶抑制剂：设计、合成、蛋白质配体 X 射线结构和生物学评价

  摘要：

  描述了一系列新一代 SARS-CoV PLpro 抑制剂的设计、合成、X 射线晶体结构、分子建模和生物学评价。一种新的先导化合物3 (6577871) 通过对多样化化学库的高通量筛选得到鉴定。随后，我们进行了先导优化和结构-活性研究，以提供一系列改进的抑制剂，这些抑制剂对 SARS-CoV 感染的 Vero E6 细胞显示出有效的 PLpro 抑制和抗病毒活性。有趣的是，( S )-Me 抑制剂15h（酶 IC 50 = 0.56 μM；抗病毒 EC 50 = 9.1 μM）和相应的 ( R )-Me 15g (IC 50= 0.32 μM；antiviral EC 50 = 9.1 μM) 是该系列中最有效的化合物，具有几乎相同的酶抑制和抗病毒活性。15g结合的 SARS-CoV PLpro的蛋白质配体 X 射线结构和与PLpro 对接的15小时的相应模型提供了对配体结合位点相互作用的有趣分子洞察。

  DOI：

  10.1021/jm1004489

文献信息

• COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES
  申请人：Ghosh Arun K.

  公开号：US20110269834A1

  公开（公告）日：2011-11-03

  Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).

  本文描述了化合物和组合物，以及使用这些化合物和组合物治疗呼吸道疾病和疾病，如严重急性呼吸综合征（SARS）的方法。
• Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Protein−Ligand X-ray Structure and Biological Evaluation
  作者：Arun K. Ghosh、Jun Takayama、Kalapala Venkateswara Rao、Kiira Ratia、Rima Chaudhuri、Debbie C. Mulhearn、Hyun Lee、Daniel B. Nichols、Surendranath Baliji、Susan C. Baker、Michael E. Johnson、Andrew D. Mesecar

  DOI：10.1021/jm1004489

  日期：2010.7.8

  design, synthesis, X-ray crystal structure, molecular modeling, and biological evaluation of a series of new generation SARS-CoV PLpro inhibitors are described. A new lead compound 3 (6577871) was identified via high-throughput screening of a diverse chemical library. Subsequently, we carried out lead optimization and structure−activity studies to provide a series of improved inhibitors that show potent

  描述了一系列新一代 SARS-CoV PLpro 抑制剂的设计、合成、X 射线晶体结构、分子建模和生物学评价。一种新的先导化合物3 (6577871) 通过对多样化化学库的高通量筛选得到鉴定。随后，我们进行了先导优化和结构-活性研究，以提供一系列改进的抑制剂，这些抑制剂对 SARS-CoV 感染的 Vero E6 细胞显示出有效的 PLpro 抑制和抗病毒活性。有趣的是，( S )-Me 抑制剂15h（酶 IC 50 = 0.56 μM；抗病毒 EC 50 = 9.1 μM）和相应的 ( R )-Me 15g (IC 50= 0.32 μM；antiviral EC 50 = 9.1 μM) 是该系列中最有效的化合物，具有几乎相同的酶抑制和抗病毒活性。15g结合的 SARS-CoV PLpro的蛋白质配体 X 射线结构和与PLpro 对接的15小时的相应模型提供了对配体结合位点相互作用的有趣分子洞察。
• X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases
  作者：Yahira M. Báez-Santos、Scott J. Barraza、Michael W. Wilson、Michael P. Agius、Anna M. Mielech、Nicole M. Davis、Susan C. Baker、Scott D. Larsen、Andrew D. Mesecar

  DOI：10.1021/jm401712t

  日期：2014.3.27

  Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV). A number of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63. Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is observed. X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead (15g) and the most potent analogues 3k and 3j, featuring a monofluoro substitution at para and meta positions of the benzyl ring, respectively. Finally, the less lipophilic bis(amide) 3e and methoxypyridine 5c exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.
• [EN] COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LE TRAITEMENT DES MALADIES RESPIRATOIRES
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2010022355A1

  公开（公告）日：2010-02-25

  Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).
• [EN] COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DES CORONAVIRUS
  申请人：[en]CLEAR CREEK BIO, INC.

  公开号：WO2023064493A1

  公开（公告）日：2023-04-20

  This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.